Insightec raises another $150m for incisionless neurosurgery platform
By Admin | March 18, 2020
Insightec announced that it signed definitive agreements for a $150 million Series F financing round with a post-money valuation of $1.3 billion.
The Haifa, Israel–based company is the developer of the Exablate Neuro incisionless neurosurgery platform. Insightec touts the Exablate Neuro as the first MR-guided focused ultrasound device to win FDA approval for treating certain movement disorders in people suffering from essential tremor and tremor-dominant Parkinson’s disease who have not responded to medication.
For more information please read, Insightec raises another $150m for incisionless neurosurgery platform, by Mass Device.
